The Novartis-Avidity deal has set a new benchmark for RNA biotech valuations. Other pharmaceutical giants are likely eyeing similar acquisitions to stay competitive in this rapidly evolving space.
Companies with proven RNA platforms and promising pipelines could command significant premiums as acquisition targets. The ยฃ12 billion Avidity deal shows just how much big pharma is willing to pay for the right technology.
Getting positioned before the next wave of deals could be crucial. These companies represent some of the most innovative approaches to treating previously untreatable genetic diseases, making them prime takeover candidates.
Novartis's ยฃ12 billion acquisition of Avidity Biosciences has created a ripple effect across the biotech sector. This premium deal signals that large pharmaceutical companies are willing to pay top dollar for innovative RNA-based therapeutics, particularly those targeting rare genetic diseases. We believe this could trigger a wave of similar acquisitions as competitors scramble to build their own RNA capabilities.
This group focuses on companies developing RNA-based treatments and gene therapies, operating in a high-growth but research-intensive market. These are typically clinical-stage biotechnology firms with innovative drug delivery platforms. The sector carries higher risk due to regulatory hurdles and lengthy development timelines, but offers significant upside potential if treatments reach market successfully.
Each company was selected for its promising RNA technology platform or pipeline of rare disease treatments that could make them attractive acquisition targets. Our analysts identified firms with innovative approaches to RNA interference, gene editing, and targeted therapeutics - the same areas that made Avidity so valuable to Novartis. These represent potential beneficiaries of ongoing industry consolidation.
Novartis's $12 billion acquisition of Avidity Biosciences underscores the high value of RNA-based treatments for rare diseases. This deal could spark a wave of similar acquisitions, creating opportunities for other biotech companies with innovative RNA platforms.
Market-cap breakdown for the 'Riding The RNA M&A Wave' basket, showing total market capitalisation and constituent weights.
RNA: $6.36B
ALNY: $60.94B
IONS: $11.40B
+4
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
์ด ์์ฐ๋ค์ ํฌ์ํ๋ค๋ฉด:
12๊ฐ์ ํ ์์ ๊ฐ์น:
+247.06%
์ ๋๋ฆฌ์คํธ๋ค์ ์ด ๊ทธ๋ฃน์ ์์ฐ์ด ํฅํ 1๋ ๊ฐ ํ๊ท 247.06% ์ฑ์ฅํ ๊ฒ์ผ๋ก ์์ํฉ๋๋ค.
์ด ๊ทธ๋ฃน์ ์์ฐ 14๊ฐ ์ค 11๊ฐ๊ฐ ์ ๋ฌธ ์ ๋๋ฆฌ์คํธ๋ก๋ถํฐ ๋งค์ ์๊ฒฌ์ ๋ฐ์์ต๋๋ค.
์ด ๋ฐ์ค์ผ์ ์ ์ฒด ์คํ ๋ฆฌ๋ฅผ ํ์ธํ์ธ์. ๋ฆฌ์คํฌ์ ์ ์ฌ๋ ฅ์ ๋ค๋ฃฌ ์์ธ ๊ธฐ์ฌ๋ฅผ ์ฝ์ด๋ณด์ธ์.
์ธ์ฌ์ดํธ ์ ์ฒด ์ฝ๊ธฐ
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
